What Wegovy actually is
Wegovy is a prescription-only medicine containing semaglutide, made by Novo Nordisk. Semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating. GLP-1 tells your brain you are full, slows how quickly food leaves your stomach, and supports blood-sugar control. Wegovy copies that signal, so most people on it feel satisfied on smaller portions and spend far less time thinking about food.
The same molecule appears under other brand names, which causes endless confusion:
| Brand | Form | UK licence |
|---|---|---|
| Wegovy | Weekly injection (up to 2.4 mg; 7.2 mg approved Jan 2026) and daily tablet (approved June 2026) | Weight management |
| Ozempic | Weekly injection (up to 2 mg) | Type 2 diabetes only. Not weight loss |
| Rybelsus | Daily tablet (up to 14 mg) | Type 2 diabetes only |
If your goal is weight management, the licensed semaglutide product is Wegovy. Not Ozempic, and not Rybelsus. Our Ozempic guide explains why that distinction matters for safety and supply.
What the trials found
Wegovy has one of the deepest evidence bases of any obesity medicine:
| Trial | Who | Result |
|---|---|---|
| STEP 1 (2021) | Adults with obesity or overweight, without diabetes | Average weight loss of 14.9% over 68 weeks at 2.4 mg, versus 2.4% on placebo |
| STEP UP (2025) | Adults with obesity, testing the 7.2 mg dose | Average weight loss of 20.7% over 72 weeks |
| SELECT (2023) | People with cardiovascular disease and overweight/obesity, without diabetes | 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) |
| OASIS 4 (2025) | Adults with obesity testing the 25 mg tablet | Average weight loss of 13.6% over 64 weeks (16.6% with full adherence) |
The SELECT result is the one that changed the conversation: Wegovy was the first weight-management medicine shown to cut heart attacks and strokes directly. Not just via weight loss. NICE has since recommended semaglutide for reducing cardiovascular risk in people with established heart disease and obesity (TA1152).
Doses: 2.4 mg, 7.2 mg, and the new pill
The Wegovy injection uses a gradual escalation schedule, stepping up every four weeks so your body adjusts: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg. Most people reach 2.4 mg by week 17, but staying longer at a lower dose is fine if you are losing steadily and side effects are an issue.
Two big updates changed the picture in 2026:
- Wegovy 7.2 mg (January 2026). The MHRA approved a higher dose for adults with obesity. Roughly triple the old maximum. In STEP UP it produced average weight loss of 20.7%. It is available privately now; NICE is appraising it for NHS use.
- The Wegovy pill (11 June 2026). A once-daily oral semaglutide tablet (target dose 25 mg). The first oral GLP-1 licensed for weight management in the UK. It has strict fasting rules. Our Wegovy pill guide covers it in full.
Who can get Wegovy in the UK
On the NHS
Under NICE TA875 (2023), semaglutide 2.4 mg is recommended for adults with a BMI of at least 35 kg/m² plus a weight-related condition (lower thresholds for some ethnic backgrounds). But it comes with two big limits: it must be prescribed within a specialist weight management service, and for a maximum of two years. In practice, NHS access depends heavily on whether your local integrated care board commissions a Tier 3 service with capacity.
Privately
The majority of UK Wegovy users go private: an online consultation, a UK-registered prescriber, and dispensing by a GPhC-registered pharmacy with refrigerated delivery. Any provider that does not verify your identity, weight and medical history is breaking the rules. Our ID checks guide explains what proper verification looks like. iGovy.co.uk manually verifies Wegovy providers against those exact standards, which is why we point readers there.
Side effects in brief
Nausea, diarrhoea, vomiting and constipation are the common ones. Mostly mild to moderate and worst during dose increases. Rarer but serious risks include acute pancreatitis (the MHRA strengthened this warning in 2026 for all GLP-1s) and gallbladder problems. The MHRA has also flagged a rare eye condition, NAION (sudden vision loss), with semaglutide. Seek urgent care for any sudden change in vision.
Severe, persistent stomach pain (especially to the back, with vomiting), sudden vision changes, signs of a serious allergic reaction, or severe dehydration. Report suspected side effects via the MHRA Yellow Card scheme. Full detail in our side effects guide.
Frequently asked questions
Is Wegovy the same as Ozempic? +
They contain the same drug (semaglutide) but they are different products with different licences. Wegovy is licensed for weight management at higher doses (up to 2.4 mg, and 7.2 mg from 2026). Ozempic is licensed only for type 2 diabetes. Using Ozempic for weight loss is off-label in the UK.
How much weight will I lose on Wegovy? +
In STEP 1, people lost an average of 14.9% of body weight over 68 weeks at 2.4 mg. In STEP UP, the 7.2 mg dose averaged 20.7%. Individual results vary with dose, adherence, diet, activity and sleep.
Can I get Wegovy on the NHS? +
Yes, under NICE TA875, but only through specialist weight management services, for adults with a BMI of at least 35 kg/m² plus a weight-related condition, and for a maximum of two years. Local availability varies, so many people use private providers.
What is the difference between the Wegovy injection and the Wegovy pill? +
Same drug, different format. The injection is weekly (up to 2.4 mg or 7.2 mg); the pill is daily (target 25 mg) and must be taken on an empty stomach with a small sip of water, waiting 30 minutes before food. The pill was MHRA-approved on 11 June 2026.
What happens if I miss a Wegovy dose? +
Take it as soon as possible within 5 days of the missed dose. If more than 5 days have passed, skip it and take the next dose on your normal day. Do not double up.
References & official sources
Show all 8 cited sources, with study authors +
- NICE TA875. Semaglutide for managing overweight and obesity (2023): www.nice.org.uk/guidance/ta875
- NICE TA1152. Semaglutide for reducing cardiovascular risk in people with cardiovascular disease and overweight or obesity: www.nice.org.uk/guidance/ta1152
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021: www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023: www.nejm.org/doi/full/10.1056/NEJMoa2307563
- Wharton S et al. Once-Weekly Semaglutide 7.2 mg in Adults with Obesity (STEP UP). Lancet Diabetes & Endocrinology 2025: www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8/abstract
- Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). NEJM 2025: www.nejm.org/doi/full/10.1056/NEJMoa2500969
- electronic medicines compendium. Wegovy SmPC & patient leaflet: www.medicines.org.uk/emc/search?q=wegovy
- Novo Nordisk. Wegovy frequently asked questions (storage, travel, dosing): www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html